Review bladder disorders and management methods you can discuss with your patients.
November is Bladder Health Month, a month dedicated to raising awareness and promoting education about maintaining a healthy bladder, something that is of particular significance to women. This month serves as an opportunity to dispel misconceptions, provide information, and empower women to prioritize their urinary well-being.
Bladder Health Month aims to shed light on common bladder disorders and offer guidance on preventive measures and management strategies that you can discuss with your patients:
You can perhaps use this month as a way to bring up conversations about bladder health, as these topics are often surrounded by stigma and silence, preventing women from discussing their concerns openly. And there is no better supportive environment than your office, where women can share their experiences, seek advice, and access appropriate care.
Reference
Wyman JF, Burgio KL, Newman DK. Practice aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009;63(8):1177-1191. doi:10.1111/j.1742-1241.2009.02078.x
(This note was written with the help of ChatGPT.)
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More